Sedation In ICU Setting Market Size, Share and Industry Analysis By Drug/Drug Class (Propofol, Benzodiazepams (Midazolam, etc.), Dexmedetomidine, Remifentanil), and Regional Forecast 2019-2032
Table of Content:
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Guidelines for Sedation in ICU Setting – forKey Countries
4.2. Technological Advancements
4.3. Pipeline Analysis
4.4. Advantages & Disadvantages of VariousTypes of Sedation in ICU Setting by Drug Class.
5. Global Sedation in ICU Setting MarketAnalysis, Insights, and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis,Insights and Forecast – By Drug/Drug Class
5.2.1. Propofol
5.2.2. Benzodiazepams (Midazolam, etc.)
5.2.3. Dexmedetomidine
5.2.4. Remifentanil
5.2.5. Others
5.3. Market Analysis,Insights, and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Rest of World
6. North America Sedation in ICU Setting MarketAnalysis, Insights, and Forecast, 2015-2026
6.1. Key Findings /Summary
6.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class
6.2.1. Propofol
6.2.2. Benzodiazepams (Midazolam, etc.)
6.2.3. Dexmedetomidine
6.2.4. Remifentanil
6.2.5. Others
6.3. Market Analysis,Insights, and Forecast – By Country
6.3.1. U.S.
6.3.2. Canada
7. Europe Sedation in ICU Setting MarketAnalysis, Insights, and Forecast, 2015-2026
7.1. Key Findings /Summary
7.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class
7.2.1. Propofol
7.2.2. Benzodiazepams (Midazolam, etc.)
7.2.3. Dexmedetomidine
7.2.4. Remifentanil
7.2.5. Others
7.3. Market Analysis,Insights, and Forecast – By Country/Sub-region
7.3.1. U.K.
7.3.2. Germany
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Sweden
7.3.7. Norway
7.3.8. Denmark
7.3.9. Finland
7.3.10.Benelux
7.3.11.Russia
7.3.12.Rest of Europe
8. Asia Pacific Sedation in ICU Setting MarketAnalysis, Insights and Forecast, 2015-2026
8.1. Key Findings /Summary
8.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class
8.2.1. Propofol
8.2.2. Benzodiazepams (Midazolam, etc.)
8.2.3. Dexmedetomidine
8.2.4. Remifentanil
8.2.5. Others
8.3. Market Analysis,Insights, and Forecast – By Country/Sub-region
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. South Korea
8.3.5. Rest of Asia Pacific
9. Rest of World Sedation in ICU Setting MarketAnalysis, Insights and Forecast, 2015-2026
9.1. Key Findings /Summary
9.2. Market Analysis,Insights, and Forecast – By Drug/Drug Class
9.2.1. Propofol
9.2.2. Benzodiazepams (Midazolam, etc.)
9.2.3. Dexmedetomidine
9.2.4. Remifentanil
9.2.5. Others
10.Competitive Analysis
10.1 KeyIndustry Developments
10.2 GlobalMarket Share Analysis (2018)
10.3 Competition Dashboard
10.4 Comparative Analysis – Major Players
10.5 CompanyProfiles (Overview, Products & services, SWOT analysis, Recentdevelopments, strategies, financials (based on availability))
10.5.1.Astra Zeneca
10.5.2.GlaxoSmithKline
10.5.3.Mylan N.V.
10.5.4.Fresenius Kabi
10.5.5.Teva Pharmaceutical Industries
10.5.6.B. Braun Medical
10.5.7.Aspen Holdings
10.5.8.Other prominent players
11. Strategic Recommendations
- REPORT UPDATE
IN PROCESS - 2019-2032
(In Process) - 2023
(In Process)
Healthcare Clients
Related Reports
